Navigation Links
Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
Date:12/12/2012

th OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRMEV Prescribing Information, available at www.OFIRMEV.com or www.cadencepharm.com.

Forward-Looking Statements Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, without limitation, statements regarding the anticipated closing date for the acquisition of Incline by The Medicines Company, the potential for Cadence to receive payments related to that transaction, and the potential for continued growth in sales of OFIRMEV, which speak only as of the date hereof. Cadence's actual future results may differ materially from Cadence's current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: the risk that the closing of the Incline acquisition may be delayed or may not occur at all; and Cadence's dependence on the successful commercialization of OFIRMEV, which is Cadence's only product; and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the SEC from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and the company undertakes no obligation to revise or update this pres
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cadence Pharmaceuticals to Host Analyst and Investor Day
2. Cadence to Open Finished Medical Device Facility
3. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
4. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
5. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
6. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
7. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
8. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2012 Financial Results On August 2, 2012
9. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
10. Oramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clinical Trials
11. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014 A victim of medical ... doctor with a history of alcohol abuse, a ... Yes on Prop 46 today, highlighting how Prop 46 will ... alcohol testing. The ad pictures a doctor ... "911-Report To ER."  Proposition 46 will enact the first law ...
(Date:10/17/2014)... , Oct. 17, 2014 The following ... Technology Policy: The Green Park Collaborative ... public and private payers, medical device and pharmaceutical ... other experts January 12, 2015 at its first ... of weight loss treatments.  Participants will discuss study ...
(Date:10/17/2014)... Conn. , Oct. 17, 2014  UBM Medica ... online community for endocrinologists and other clinicians who treat ... comprehensive coverage on effective use of insulin .  ... eventually require insulin replacement therapy – daily ... for the progressive decline in the function of pancreatic ...
Breaking Medicine Technology:Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3
... 2011 What:   Investigators ... of FDA,s 510(k) regulatory pathway—through which more than 90% ... it. The study is the most comprehensive survey to ... Center for Devices and Radiological Health (CDRH) is currently ...
... SOUTH SAN FRANCISCO, Calif., May 18, 2011 Onyx ... the presentation of several studies evaluating carfilzomib, a selective, ... inhibitor, in hematological cancers at the 47th American Society ... in Chicago, IL. "The data that will ...
Cached Medicine Technology:Findings From Largest Industry Assessment of 510(k) Process to be Released on May 24, 2011 2Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 2Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 3Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 4Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 5Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 6Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting 7
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Having been working ... a good knowledge of customer needs. According to James, one ... covered with dazzling sequins, or with high-low skirts that add ... a huge demand. Recently, LunaDress has unveiled its new selection ... of fact, the company’s brand new items are available in ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... 12 HOUR for use in treating symptoms of seasonal allergic ... a combination of desloratadine 2.5 mg and pseudoephedrine sulfate, USP ... in persons above 12 years of age. The drug ... non-nasal symptoms occurring due to seasonal allergic rhinitis. Two ...
... India’s National Institute of Immunology are reported to have ... how the tuberculosis (TB) bacteria survives in the human ... and more effective medicines to combat the disease, which ... world annually. The research team led by Rajesh S. ...
... new survey has found that many British workers are not averse ... be sent in by text messages or the typical cough and ... is the widespread dissatisfaction with holiday allowance for British workers, who ... ,'Early February is a very popular time for ...
... leaders, particularly in South Asia to prohibit smoking among the ... the British Medical Journal (BMJ). The help of the Muslim ... ,The researchers analyzed data on the prevalence of smoking ... Smoking rates in each of these countries is significantly higher ...
... topic for several years, gaining momentum over the past one ... physiological responses to them. A new study, published in the ... effect of types of placebo devices Vs pills on patients ... placebos to gauge the effectiveness of novel treatment methods, but ...
... of Health said that conventional tests fail to identify smaller blood ... sign because they do not have the bulky clogs in main ... shortness of breath and are at an increased risk of a ... is very common among both men and women and causes maximum ...
Cached Medicine News:Health News:Placing a Finger on Responses to Placebo Types 2
... surface preparation is the Leica SM2500 sledge ... ,Ultramilling is often a viable alternative to ... preparation. Especially with difficult specimens, where hard ... side in one specimen block, the results ...
... The Trellis Infusion Catheter enables the physician ... physician-specified fluid, and disperse the agent by ... The Trellis is a multi-lumen catheter with ... end and infusion holes located between these ...
... The SENSAR® Acrylic IOL with OptiEdge ... performance, long-term refractive stability, and excellent handling. ... has had no reports of vacuoles; the ... internal reflections and provide 360 degrees of ...
... acrylic foldable single-piece posterior chamber lenses are ... human crystalline lens in the visual correction ... age and older. The optical portion consists ... material. These lenses have biconvex optics and ...
Medicine Products: